Accuray Incorporated Q4 Operating Expenses US
This article provides an in-depth financial analysis of Accuray Incorporated's Q4 operating expenses in the US, highlighting key figures and trends. It breaks down the components of their expenditures, offering insights into the company's financial health and operational efficiency during the quarter.
Accuray Incorporated 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:ARAY) 2026-08-20
This article announces that Accuray Incorporated has published its Q4 2026 earnings call presentation. The presentation was released in conjunction with their earnings call on August 20, 2026. Seeking Alpha's transcripts team prepared this content.
Aug 19 (Reuters) - Accuray Incorporated Q4 Ne
This article is a Reuters news brief from August 19, reporting on Accuray Incorporated's Q4 results. The content is incomplete, only providing the headline and indicating that it's a financial news update.
Accuray Q4 FY26 slides: transformation gains amid revenue decline
Accuray Incorporated reported a significant 21% year-over-year revenue decline in Q4 FY26, primarily due to falling product sales, although its service revenue grew. Despite a GAAP net loss, the company achieved improved adjusted EBITDA through cost optimization and transformation initiatives, exceeding initial targets. Accuray faces ongoing challenges from geopolitical uncertainties, especially in China, and declined to provide FY27 guidance.
Earnings call transcript: Accuray posts mixed Q4 2026 results as revenue slips
Accuray Inc. reported mixed financial results for Q4 fiscal year 2026, beating EPS estimates but missing revenue forecasts. The company's revenue declined significantly year-over-year, primarily due to a sharp drop in product sales, especially from China, though service revenue saw growth. Accuray did not provide formal guidance for fiscal year 2027 due to geopolitical and tariff uncertainties but outlined expectations for continued service revenue growth and improved margins.
Accuray Reports $100.9 Million Fourth-Quarter Revenue and $1.9 Million Net Loss
Accuray (ARAY) reported fourth-quarter fiscal 2026 revenue of $100.9 million, a 21% decrease year-over-year, and a GAAP net loss of $1.9 million. For the full fiscal year 2026, the company recorded $401.9 million in revenue and a net loss of $49.2 million, declining to provide fiscal 2027 guidance. Insider trading data shows STEVEN F MAYER made three purchases of ARAY stock totaling 250,000 shares for $134,675, while hedge funds showed mixed activity with 59 increasing and 86 decreasing their positions.
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
Accuray Incorporated announced its financial results for the fourth quarter and fiscal year ended June 30, 2026. The company reported a 21% decrease in total net revenue for the fourth quarter and a 12% decrease for the full fiscal year, but saw service revenue increase by 6% and 4% respectively. Accuray highlighted its successful transformation plan, exceeding its cost and margin improvement target, and a comprehensive financing transaction that enhanced liquidity.
Accuray: Fiscal Q4 Earnings Snapshot
Accuray Inc. reported a fiscal fourth-quarter loss of $1.9 million, or 2 cents per share, on revenue of $100.9 million. For the full fiscal year, the company's loss widened to $49.2 million, or 40 cents per share, with total revenue reaching $401.9 million. The company's shares were trading at 29 cents, significantly down from $1.51 a year prior.
ARAY Looks 76.5% Undervalued on GF Value™
Accuray Inc (ARAY) is set to release its Q4 earnings on August 19, 2026. Despite a GF Value™ suggesting it is 76.5% undervalued, its low Price-to-Sales ratio and weak GF Score™ (44/100) point to significant financial challenges including persistent losses, negative cash flow, and high bankruptcy risk. However, insider buying and mixed guru activity provide some cautious optimism for potential recovery.
Earnings Preview: Accuray to Report Financial Results Post-market on August 19
Accuray (NASDAQ: ARAY) is scheduled to announce its quarterly earnings post-market on August 19. Analysts are projecting earnings per share of $0.02 and revenue of $111.45 million. The company's stock has seen varied performance recently, including an analyst upgrade from Citigroup and significant insider stock purchases.
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
Accuray Incorporated has announced two key leadership appointments to advance its strategic priorities and transformation plan for sustainable, profitable growth. Todd Brown will lead the newly created Enterprise Performance Optimization organization, focusing on improving operational execution, lowering costs, and enhancing supply chain efficiency. Sofiane Laoussadi has been appointed Senior Vice President of Global Services & Solutions to lead the global services organization, aiming to improve customer experience and expand solution-based offerings.
Accuray names two executives to lead transformation efforts
Accuray Incorporated has announced the appointment of Todd Brown as Senior Vice President for a new Enterprise Performance Optimization organization and Sofiane Laoussadi as Senior Vice President, Global Services & Solutions. These appointments are part of the company's "Transformation Phase II" priorities, aimed at enhancing operational execution, optimizing cost structure, and delivering value to customers and shareholders. Brown will focus on working capital, supply chain efficiency, and cost optimization, while Laoussadi will lead global service delivery and customer support.
Accuray (NASDAQ: ARAY) seeks approval for $55M recapitalization, dilution and reverse split
Accuray (NASDAQ: ARAY) is seeking stockholder approval for a significant financing and recapitalization plan, including issuing $55 million in Series A Convertible Preferred Stock and warrants, and a reverse stock split. The plan aims to strengthen liquidity, reduce leverage, and achieve Nasdaq compliance, but will cause substantial dilution for existing shareholders and increase TCW's influence. Stockholders will vote on these proposals at a virtual special meeting on October 6, 2026, with the Board unanimously recommending approval despite the potential for significant dilution and increased influence from TCW.
Accuray Transfers Listing to Nasdaq Capital Market
Accuray (ARAY) has received Nasdaq approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective August 6, 2026. This transfer grants the company an additional 180 days, until February 1, 2027, to meet Nasdaq's minimum bid price requirement. Analysts currently rate ARAY as "Hold" with a $0.35 price target, while TipRanks' AI Analyst Spark rates it "Underperform" due to weak financial performance and technical indicators.
Accuray Announced Transfer or Voluntary Withdrawal of Listing
Accuray (ARAY) has received Nasdaq approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective August 6, 2026. The company retains its ARAY symbol and has an additional 180 days, until February 1, 2027, to meet the $1.00 bid price requirement. This information is based on an original SEC Filing.
Radiation therapy company Accuray will discuss results Aug. 19
Accuray (NASDAQ: ARAY) is scheduled to report its fourth quarter fiscal 2026 financial results on August 19, 2026, for the period ending June 30, 2026. Company management will host a conference call that day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. A live webcast and replay of the call will be accessible via the Investor Relations section of Accuray's website.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (NASDAQ: ARAY) will report its fourth-quarter fiscal year 2026 financial results on August 19, 2026. The company will host a conference call and webcast for investors at 1:30 p.m. PT/4:30 p.m. ET to discuss the results, which concluded on June 30, 2026. Accuray specializes in radiation therapy solutions for cancer treatment, aiming to improve patient outcomes.
Neuberger Berman Group (ARAY) discloses 5.48M Accuray shares in 13G/A filing
Neuberger Berman Group LLC and its affiliates have disclosed an amended passive investment in Accuray Inc. (ARAY) via a Schedule 13G/A filing. The group beneficially owns 5,484,393 shares, representing 4.6% of Accuray’s common stock, with shared voting and dispositive power. Neuberger Berman Investment Advisers LLC separately holds 5,057,218 shares, or 4.3% of the class.
Accuray | SCHEDULE 13G/A: Others
This article consists solely of the title "Accuray | SCHEDULE 13G/A: Others" and the content "Document". It indicates the filing of a Schedule 13G/A, suggesting an amendment to a previous beneficial ownership report for Accuray. However, no detailed information about the filing or the company is provided.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (NASDAQ: ARAY) announced it will report its financial results for the fourth quarter of fiscal year 2026 on August 19, 2026. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss these results, with dial-in and webcast replay options available for investors. Accuray, headquartered in Madison, Wisconsin, specializes in radiation therapy solutions for various cancer treatments.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (NASDAQ: ARAY) is scheduled to release its financial results for the fourth quarter of fiscal year 2026 on August 19, 2026. The company will host a conference call and webcast at 1:30 p.m. PT/4:30 p.m. ET to discuss the results, which will cover the period ending June 30, 2026. Details for accessing the call, replay, and live webcast are provided.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (ARAY) announced it will report its financial results for the fourth quarter of fiscal year 2026 on August 19, 2026. A conference call hosted by company management will take place at 1:30 p.m. PT/4:30 p.m. ET, with dial-in and webcast details provided for investors and the public. Accuray, headquartered in Madison, Wisconsin, specializes in radiation therapy solutions for oncology and neuro-radiosurgery.
Accuray Number of Employees 2026 | Employee Count & Headcount Data
Accuray, Inc. (ARAY) had 909 employees worldwide as of March 2026, representing an 8.3% decline from 2023. The company is actively hiring, with 40 active job postings in 2026, though this is a 51.9% decline from 2025. The workforce is concentrated in North America, and overall employee sentiment is negative and declining.
Form S-3 Accuray Incorporated For: 31 July By Investing.com
This article from Investing.com announces the filing of Form S-3 by Accuray Incorporated for the period ending July 31. It is a brief administrative notice indicating a regulatory filing has been made by the company. The content primarily consists of navigational elements and market data rather than detailed analysis of the filing itself.
Price to sales forward of Accuray Incorporated – NASDAQ:ARAY
This article provides financial information for Accuray Incorporated (NASDAQ: ARAY), specifically focusing on its price to sales forward metric. It appears to be a data point or a snapshot from a financial platform like TradingView, indicating the value and change of this financial ratio. The core content is a single data point related to ARAY's financial performance.
Accuray (ARAY) files S-3 to register 6.8M warrant shares for resale
Accuray Incorporated has filed a Form S-3 shelf registration statement to allow for the resale of up to 6,834,308 shares of common stock by certain lending investors. These shares are issuable upon the exercise of Super Premium, Premium, and Penny Warrants previously granted in connection with the company's senior secured financing. Accuray will not receive proceeds from the resales but would receive cash if the warrants are exercised, which it intends to use for general corporate purposes.
Accuray Restructures Capital and Governance to Boost Flexibility
Accuray has announced a capital and governance restructuring, including a $55 million convertible preferred stock issuance, cancellation of existing warrants, and a reverse stock split, all aimed at enhancing financial flexibility. The company is also streamlining its board, focusing on operational transformation, and pursuing strategic partnerships to drive innovation and growth. Despite challenges like weakening operating performance, these moves are intended to strengthen Accuray's market position.
Accuray Enters Agreements With TCW Asset Management to Boost Financial Position, Liquidity
Accuray has entered into new financing agreements with TCW Asset Management Company LLC, replacing its existing term loan and revolving credit facilities. These new agreements are expected to enhance the company's financial position and provide increased liquidity, supporting its strategic initiatives and operations.
Accuray Inc (ARAY) Financial Health: Profitability & Balance Sheet Analysis
Accuray Inc (ARAY) currently holds a financial score of 7.25, ranking 92 out of 199 in its industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 7.42% year-over-year to $104.84M, and its net profit saw a significant year-over-year decrease of 810.18%. Key financial metrics like cash and cash equivalents, total assets, and free cash flow have not been fully disclosed by the company.
ARAY|Accuray Inc|Price:0.232|Chg%:-0.011
This article provides a comprehensive stock analysis of Accuray Inc (ARAY), highlighting its current stock score, financial health, valuation, and market performance. It notes the company's stable fundamentals and high growth potential, despite a recent weak stock market performance. The analysis also includes institutional ownership, analyst ratings, and peer comparisons, suggesting a potential for range-bound swing trading.
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
Accuray Incorporated has announced a comprehensive plan to strengthen its financial position and accelerate innovation. This involves a significant financial agreement with TCW Asset Management Company LLC, including deleveraging and an equity investment, along with strategic partnerships with companies like Samsung HME America and RaySearch Laboratories to enhance technology and operational performance. Accuray will also continue investing in its core proprietary technologies and embarking on a second phase of transformation focused on differentiated innovation, cost reduction, and expanded market reach.
Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation
Accuray Incorporated has unveiled a comprehensive plan aimed at improving its financial health, transforming its business strategy, rolling out new technology, and enhancing operational efficiency. This includes significant financial restructuring with TCW Asset Management, strategic partnerships with companies like Samsung HME America and RaySearch Laboratories, and further development of its core technologies. The initiatives are designed to accelerate innovation, improve performance, reduce costs, and ultimately drive long-term value creation for shareholders and better outcomes for cancer patients.
Beverly Huss and Anne LeGrand resign from Accuray board
Accuray announced that board members Beverly Huss and Anne LeGrand resigned from their positions, effective July 29, 2026. The company stated that their resignations were not due to any disagreement with the company or the board. Information regarding their replacements and specific background details was not disclosed.
Accuray Raises $55M Preferred, Converts $40M Debt; Amends TCW Loan and Cancels Warrants
Accuray (ARAY) announced a recapitalization plan involving a $55.0 million Series A Convertible Preferred Stock agreement, which includes $15.0 million in cash and converts $40.0 million of debt, pending stockholder approval and a reverse stock split. The company also amended its financing with TCW, securing a covenant holiday until 2027, revising liquidity terms, and adding $5.0 million in delayed draw capacity while converting its revolver to an asset-based facility. This strategic move aims to simplify Accuray's capital structure by issuing seven-year penny warrants for up to 15.3 million shares and canceling approximately 27.6 million legacy investor warrants.
Accuray Incorporated announced that it expects to receive $15 million in funding
Accuray Incorporated is set to receive $15 million in funding through a Securities Purchase Agreement with existing investors. The company will issue 15,000 Series A Convertible Preferred Stocks at $1,000 per share. Dividends on these preferred stocks will accrue at 8% per annum, and the issuance is contingent on stockholder approval.
Accuray Inc (ARAY) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Accuray Inc (ARAY), including its price momentum score of 4.55 within the Healthcare Equipment & Supplies industry. It identifies current support at $0.21 and resistance at $0.28, suggesting suitability for range-bound swing trading. The analysis also details various technical indicators and moving averages, offering insights into potential buy, sell, or neutral signals.
Accuray Inc (ARAY) Institutional Confidence
Accuray Inc (ARAY) has an institutional shareholding score of 7.00, placing it 78th in its industry, with 72.22% of shares held by institutions, a 5.61% decrease quarter-over-quarter. James Simons is the largest institutional shareholder. The article also lists major institutional shareholders and their recent activity.
Accuray Inc (ARAY) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Accuray Inc (ARAY), noting its current risk score of 2.65 and ranking it 145 out of 199 in the Healthcare Equipment & Supplies industry. Key metrics like a beta of 1.34 and various volatility and drawdown figures are presented, indicating the stock's sensitivity to market movements. The assessment also includes return, Sharpe ratio, skewness, and liquidity data to give a comprehensive view of ARAY's investment risk profile.
Accuray Inc (ARAY) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Accuray Inc (ARAY), outlining its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over recent quarters, and a list of related ETFs that include ARAY. The data includes specific companies, their proportion of shares, and changes in their holdings.
Accuray Inc (ARAY) Cash Flow - Tradingkey.com
This article provides a detailed cash flow statement for Accuray Inc (ARAY), including quarterly and annual data for operating cash flow, investing cash flow, and financing cash flow. It lists various line items such as net income from continuing operations, capital expenditures, and debt issuance/repayment. The article also includes a section of FAQs defining these cash flow types and highlighting Accuray Inc's recent performance in these areas.
Accuray Inc (ARAY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Accuray Inc (ARAY) by business segments and geographical regions, with data updated as of April 6. The company's revenue is segmented into 'Service' and 'Product', with 'Service' contributing a larger proportion. Regional revenue contributions are also shown, highlighting Europe, Middle East, India, and Africa as the largest segment.
Accuray Inc (ARAY) Earnings Forecast: Future EPS & Revenue Growth Estimates
Accuray Inc (ARAY) has an earnings forecast score of 6.00, ranking 174th in the Healthcare Equipment & Supplies industry. The average analyst price target for ARAY is $3.88, with one analyst currently rating the stock as "Hold". The company is expected to report revenue of $105.30 million for the next quarter and an EPS of -$0.10.
ARAY|Accuray Inc|Price:0.238|Chg%:+0.000
This article provides a detailed company profile for Accuray Inc (ARAY), a radiation therapy company. It outlines the company's business scope, including its CyberKnife and TomoTherapy platforms for cancer treatment, and details its financial data and market performance. Key information such as executive shareholdings, top shareholders, and institutional ownership is also presented.
Accuray Incorporated Revenue Breakdown – NASDAQ:ARAY
Accuray Incorporated (NASDAQ: ARAY) generated $458.50 million USD in revenue last year. The Oncology Systems Products segment was its top performer, contributing $237.58 million USD. Geographically, Europe, India, the Middle East, and Africa were the largest contributors with $144.26 million USD.
Price to sales forward of Accuray Incorporated – BX:XEJ
This article provides financial data for Accuray Incorporated (BX:XEJ), specifically its price-to-sales forward ratio. It highlights the company's financial overview within the health technology sector on BX Swiss.
ARAY|Accuray Inc|Price:0.238|Chg%: +0.000
Accuray Inc (ARAY) closed at $0.238 on July 24, 2026, with a slight increase of 0.08%. The company's fundamentals are stable with high growth potential, though its valuation is considered fair. Analysts currently rate the stock as "Hold" with a target price of $0.35, suggesting a potential upside.
Enterprise value to revenue forward of Accuray Incorporated – NASDAQ:ARAY
The article discusses the enterprise value to revenue forward for Accuray Incorporated (NASDAQ: ARAY). It indicates that financial information specific to this metric would be displayed, likely within a table or chart, but the content provided is primarily navigational and structural rather than data-driven. The article is hosted on TradingView, a financial platform offering various market data and analysis tools.
Accuray Incorporated (XEJ) Q2 2025 Earnings Report - Results, Call & Slides
This article provides the Q2 2025 earnings report for Accuray Incorporated (XEJ), detailing an EPS beat of €0.04 with actual EPS at €0.02, compared to a consensus of -€0.02. The company also surpassed revenue expectations, reporting €101.75M against an expected €96.64M, marking an 8.33% year-over-year growth. The earnings announcement took place on February 5, 2025, with the next earnings report estimated for August 19, 2026.
Accuray Incorporated (XEJ) Q1 2025 Earnings Report - Results, Call & Slides
Accuray Incorporated (XEJ) released its Q1 2025 earnings report, showing an actual EPS of -€0.04, which beat the consensus EPS of -€0.04. The company's revenue for the quarter was €88.94M, surpassing the expected €85.44M, despite a slight year-over-year revenue decrease of 2.26%. The next earnings report is estimated for August 19, 2026.
Accuray Incorporated Recalls 48 Units Cyberknife Treatment Deliver System Equipped with the Xchange Robotic Collimator Changer
Accuray Incorporated has voluntarily recalled 48 units of its Cyberknife Treatment Deliver System equipped with the Xchange Robotic Collimator Changer. The recall, classified as Class II, was initiated due to a software issue where a collimator might not fully dock, potentially falling if motion is initiated in the treatment room. The recalled units were distributed worldwide, and the firm began the recall process on June 16, 2026.
